The Role of P27 in Breast Epithelial Progenitors and Breast Cancer Risk

P27 在乳腺上皮祖细胞和乳腺癌风险中的作用

基本信息

  • 批准号:
    8633710
  • 负责人:
  • 金额:
    $ 20.13万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2014
  • 资助国家:
    美国
  • 起止时间:
    2014-02-01 至 2019-01-31
  • 项目状态:
    已结题

项目摘要

Existing biomarkers and cancer prevention strategies are limited as the biology of breast tumor initiation remains poorly understood. We aim to elucidate mammary epithelial cells that participate in tumorigenesis as a means of developing markers for risk stratification and targets for prevention. Important clues to the identity of these cells come from epidemiologic and our preliminary data. Early full-term pregnancy is one of the most effective protections against breast cancer in most women but not in BRCA1/2 mutation carriers. We investigated parity-associated variation in gene expression profiles of distinct cell types in normal breast tissues of nulliparous and parous women. The most significant differences were seen in CD44+ cells where many genes important in self-renewal and differentiation (e.g., p27, TGFB) were lower in parous women than in nulliparous and in parous BRCA1/2 mutation carriers. The numbers of p27+ and Ki67+ cells were also significantly lower in parous than in nulliparous women except in parous BRCA1/2 cases. The majority of p27+ cells were also estrogen receptor positive. In explant cultures of breast tissues, inhibition of TGFB increased proliferation with a concomitant decrease of p27+ cells implying that p27 due to TGFB is key for keeping breast epithelial progenitors in a quiescent state. Based on these preliminary data, we hypothesize that (1) a subset of p27+ and Ki67+ cells represent quiescent and proliferating hormone-responsive breast epithelial progenitors, respectively, (2) p27 and TGFJ3 play an important role in keeping these progenitors quiescent, (3) the number of these progenitors correlates with breast cancer risk, and (4) mechanisms regulating p27+ progenitors are perturbed in BRCA1/2 mutation carriers and this contributes to their high risk. To test these hypotheses we propose: 1. To characterize the molecular profiles of p27+ and Ki67+ human breast epithelial cells from normal breast tissue of women with different risk of breast cancer. 2. To investigate the role of p27 and signaling pathways that regulates its expression in human breast epithelial cell proliferation and differentiation. 3. To characterize the role of p27 in regulating the abundance of mammary epithelial progenitors and its effect of this on mammary tumorigenesis in animal models.
现有的生物标志物和癌症预防策略是有限的,因为乳腺癌发生的生物学仍然知之甚少。我们的目的是阐明参与肿瘤发生的乳腺上皮细胞,作为开发风险分层标记和预防目标的手段。这些细胞身份的重要线索来自流行病学和我们的初步数据。早期足月妊娠对大多数女性来说是预防乳腺癌最有效的方法之一,但对BRCA1/2突变携带者来说并非如此。我们研究了未产和已产妇女正常乳腺组织中不同细胞类型的基因表达谱的胎次相关变异。最显著的差异出现在CD44+细胞中,其中许多在自我更新和分化中重要的基因(例如p27, TGFB)在分娩妇女中低于未分娩妇女和分娩BRCA1/2突变携带者。除已产BRCA1/2病例外,已产妇女的p27+和Ki67+细胞数量也显著低于未产妇女。大多数p27+细胞也呈雌激素受体阳性。在乳腺组织的外植体培养中,抑制TGFB增加了增殖,同时p27+细胞减少,这意味着TGFB导致的p27是保持乳腺上皮祖细胞处于静止状态的关键。基于这些初步数据,我们假设(1)p27+和Ki67+细胞分别代表静止和增殖激素应答的乳腺上皮祖细胞,(2)p27和TGFJ3在保持这些祖细胞静止中起重要作用,(3)这些祖细胞的数量与乳腺癌风险相关,(4)在BRCA1/2突变携带者中调节p27+祖细胞的机制受到干扰,这导致了它们的高风险。为了验证这些假设,我们提出:1。目的研究不同乳腺癌发病风险女性正常乳腺组织中p27+和Ki67+人乳腺上皮细胞的分子特征。2. 探讨p27及其表达调控信号通路在人乳腺上皮细胞增殖和分化中的作用。3. 在动物模型中表征p27在调节乳腺上皮祖细胞丰度中的作用及其对乳腺肿瘤发生的影响。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

KORNELIA POLYAK其他文献

KORNELIA POLYAK的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('KORNELIA POLYAK', 18)}}的其他基金

Administrative Core - New therapeutic vulnerabilities in breast cancer
行政核心 - 乳腺癌的新治疗漏洞
  • 批准号:
    10261469
  • 财政年份:
    2020
  • 资助金额:
    $ 20.13万
  • 项目类别:
Epigenetic mechanisms of therapeutic resistance
治疗耐药的表观遗传机制
  • 批准号:
    10627962
  • 财政年份:
    2020
  • 资助金额:
    $ 20.13万
  • 项目类别:
Administrative Core - New therapeutic vulnerabilities in breast cancer
行政核心 - 乳腺癌的新治疗漏洞
  • 批准号:
    10627981
  • 财政年份:
    2020
  • 资助金额:
    $ 20.13万
  • 项目类别:
Epigenetic mechanisms of therapeutic resistance
治疗耐药的表观遗传机制
  • 批准号:
    10434103
  • 财政年份:
    2020
  • 资助金额:
    $ 20.13万
  • 项目类别:
New therapeutic vulnerabilities in breast cancer
乳腺癌新的治疗弱点
  • 批准号:
    10434102
  • 财政年份:
    2020
  • 资助金额:
    $ 20.13万
  • 项目类别:
Epigenetic mechanisms of therapeutic resistance
治疗耐药的表观遗传机制
  • 批准号:
    10023397
  • 财政年份:
    2020
  • 资助金额:
    $ 20.13万
  • 项目类别:
Administrative Core - New therapeutic vulnerabilities in breast cancer
行政核心 - 乳腺癌的新治疗漏洞
  • 批准号:
    10023400
  • 财政年份:
    2020
  • 资助金额:
    $ 20.13万
  • 项目类别:
New therapeutic vulnerabilities in breast cancer
乳腺癌新的治疗弱点
  • 批准号:
    10627961
  • 财政年份:
    2020
  • 资助金额:
    $ 20.13万
  • 项目类别:
New therapeutic vulnerabilities in breast cancer
乳腺癌新的治疗弱点
  • 批准号:
    10261465
  • 财政年份:
    2020
  • 资助金额:
    $ 20.13万
  • 项目类别:
Epigenetic mechanisms of therapeutic resistance
治疗耐药的表观遗传机制
  • 批准号:
    10261466
  • 财政年份:
    2020
  • 资助金额:
    $ 20.13万
  • 项目类别:

相似海外基金

Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
  • 批准号:
    495434
  • 财政年份:
    2023
  • 资助金额:
    $ 20.13万
  • 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
  • 批准号:
    10642519
  • 财政年份:
    2023
  • 资助金额:
    $ 20.13万
  • 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
  • 批准号:
    10586596
  • 财政年份:
    2023
  • 资助金额:
    $ 20.13万
  • 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
  • 批准号:
    10590479
  • 财政年份:
    2023
  • 资助金额:
    $ 20.13万
  • 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
  • 批准号:
    23K06011
  • 财政年份:
    2023
  • 资助金额:
    $ 20.13万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
  • 批准号:
    10682117
  • 财政年份:
    2023
  • 资助金额:
    $ 20.13万
  • 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
  • 批准号:
    10708517
  • 财政年份:
    2023
  • 资助金额:
    $ 20.13万
  • 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
  • 批准号:
    10575566
  • 财政年份:
    2023
  • 资助金额:
    $ 20.13万
  • 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
  • 批准号:
    23K15696
  • 财政年份:
    2023
  • 资助金额:
    $ 20.13万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
  • 批准号:
    23K15867
  • 财政年份:
    2023
  • 资助金额:
    $ 20.13万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了